ArticleDiscover oncology2026
Tolerance and response of afatinib combined with tegafur in patients with advanced biliary tract cancer after failure of gemcitabine-based systemic therapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOff-label afatinib with tegafur was attempted as a last resort option in a patient with advanced gallbladder cancer, achieving satisfactory outcomes. This study evaluated the benefits and toxicity of afatinib with tegafur in advanced biliary tract cancer (BTC).
methodsThis retrospective study included patients who received afatinib combined with tegafur after failure of gemcitabine-based systemic therapy between Oct 2017 and Dec 2024 at the First Affiliated Hospital of Anhui Medical University. Progression-free survival (PFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), and treatment-related adverse events were evaluated. Cox regression analysis and subgroup analysis were used to assess the relationship between different factors and OS.
resultsFifty-eight patients were included. Two patients achieved partial response, 28 achieved stable disease, and 28 achieved progressive disease, indicating a DCR of 51.7% and an ORR of 3.4%. Median PFS and OS were 4.0 and 6.6 months, respectively. The toxicity associated with afatinib and tegafur was generally acceptable. OS was prolonged in six patients with positive HER-2 and four patients with positive KRAS (G13D) mutations (median: 11.0 months) compared with those without mutations (median: 6.30 months) or unknown genetic status (median: 6.30 months) (P = 0.013). The multivariable Cox analysis showed that no factors were independently associated with OS (all P > 0.05).
conclusionsAfatinib with tegafur had an acceptable safety profile for advanced BTC after gemcitabine-based systemic therapy failure. The outcome of patients with low performance status and HER-2 or KRAS (G13D) mutations may be better than patients without the mutation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.